Equity Briefing: ROTH Capital sees NEPT stock poised for significant growth this year
(Thomson Reuters ONE) -
ROTH Capital Partners' analyst Joseph Pantginis, Ph.D., has reiterated a BUY
recommendation and $9 price target for shares of Neptune Technologies &
Bioressources (Nasdaq:NEPT) (TSX:NTB.TO).
"The stock is poised for significant growth this year, in our view, with key top
line results from two ongoing Phase II CaPre clinical studies conducted by
Acasti in Canada," wrote Pantginis in a note to clients.
"Data from an open label study in hypertriglyceridemia are anticipated mid-year,
and data from a randomized, double blind Phase II study are expected by the end
of 2012. These results, in addition to clinical PK/PD data garnered to date by
Acasti, will likely support the commencement of a potential pivotal trial in the
U.S. by the end of 2012."
Source: http://bit.ly/LCXafO
On Wednesday, the Neptune announced that former CEO of Imclone Systems, Dr.
Harlan Waksal, was appointed to the Neptune's Corporate Board of Directors.
Waksal currently serves as Executive Vice-President, Business & Scientific
Operations of Neptune's subsidiary Acasti Pharma Inc.
The move is being well received by industry observers and analysts, given the
Wall Street relationships and impressive experience which Waksal brings to the
Canadian firm.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Equity Briefing via Thomson Reuters ONE
[HUG#1614331]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.05.2012 - 08:55 Uhr
Sprache: Deutsch
News-ID 1117301
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 94 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Equity Briefing: ROTH Capital sees NEPT stock poised for significant growth this year
"
steht unter der journalistisch-redaktionellen Verantwortung von
Equity Briefing (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
